MoonLake Immunotherapeutics Files BLA for Sonelokimab for HS

What Happened

• On September 30, 2026, MoonLake Immunotherapeutics (MLTX) announced it submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of its tri‑specific nanobody sonelokimab for the treatment of moderate‑to‑severe hidradenitis suppurativa (HS) in adults and pediatric patients 12 years and older.
• The company said it expects FDA notification on whether the BLA is accepted for review in approximately 60 days and to receive the planned review timeline in approximately 74 days. The item was reported on Form 8‑K (Item 8.01).

Key Details

• Filing date: September 30, 2026.
• Product: sonelokimab (tri‑specific nanobody) for moderate‑to‑severe hidradenitis suppurativa.
• Indication population: adults and pediatric patients aged 12 years and older.
• Regulatory timing: FDA acceptance expected ~60 days after submission; planned review timeline expected ~74 days after submission.

Why It Matters

• This BLA submission is a major regulatory milestone that moves sonelokimab from clinical development toward potential U.S. approval and commercialization, which could materially affect MoonLake’s future revenue prospects if approved.
• The company’s next near‑term investor milestones are the FDA’s acceptance decision and the issuance of a review timeline; both are time‑bound expectations disclosed in the 8‑K but are forward‑looking and subject to regulatory and other risks described in MoonLake’s filings (including its 2025 Form 10‑K).